Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I-Metaiodobenzylguanidine (MIBG)

Pediatric Blood and Cancer

Volumn 63, Issue 3, 2016, Pages 436-442

  Trieu, Megan ^a   Dubois, Steven G ^a   Pon, Elizabeth ^a   Nardo, Lorenzo ^a   Hawkins, Randall A ^a   Marachelian, Araz ^b   Twist, Clare J ^c   Park, Julie R ^d   Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

131I metaiodobenzylguanidine (MIBG); Dosimetry; Neuroblastoma; Whole body radiation dose (WBD)

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; IRINOTECAN; VINCRISTINE; (3 IODOBENZYL)GUANIDINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROBLASTOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; WHOLE BODY RADIATION; INFANT; MIDDLE AGED; NONPARAMETRIC TEST; PRESCHOOL CHILD; RADIOTHERAPY DOSAGE; YOUNG ADULT;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84956571721     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25816     Document Type: Article

References (38)

1. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 2009;27:1007-1013.
2. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302.
3. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-418.
4. Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014;50:801-815.
5. Gaze MN, Gains JE, Walker C, Bomanji JB. Optimization of molecular radiotherapy with [131I]-meta iodobenzylguanidine for high-risk neuroblastoma. Q J Nucl Med Mol Imaging 2013:57:66-78.
6. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-2460.
7. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-236.
8. Kosmin MA, Bomanji JB, Cork NJ, Shankar A, Gaze MN. Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma. Eur J Nucl Med Mol Imaging 2012;39:597-601.
9. Modak S, Pandit-Taskar N, Kushner BH, Kramer K, Smith-Jones P, Larson S, Cheung NK. Transient sialoadenitis: A complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer 2008;50:1271-1273.
10. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011;56:191-201.
11. Clement SC, Kraal KC, van Eck-Smit BL, van den Bos C, Kremer LC, Tytgat GA, van Santen HM. Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: Report of the first two cases. J Clin Endocrinol Metab 2014;99:E112-E116.
12. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713-1721.
13. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial. Clin Cancer Res 2012:18:2679-2686.
14. DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer 2015;112:644-649.
15. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. Clin Cancer Res 2015;21:2715-2721.
16. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-1060.
17. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study. J Clin Oncol 2006;24:500-506.
18. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009;27:1020-1025.
19. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant 2015;21:673-681.
20. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: New approaches to neuroblastoma therapy consortium trial. J Nucl Med 2012;53:1155-1163.
21. Loevinger R, Budinger TF, Watson EE, Committee SoNMMIRD. MIRD primer for absorbed dose calculations. New York, NY: Society of Nuclear Medicine 1988.
22. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources: Ornl/tm-8381 v1-v7. Oak Ridge, TN: Oak Ridge National Laboratory; 1987.
23. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
24. Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, Gongora R, Manil L. A new 123I-MIBG whole body scan scoring method-Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A:256-261.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
26. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, Pearson AD, Cohn SL. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: A report for the international neuroblastoma risk group (inrg) task force. Br J Cancer 2010:102:1319-1326.
27. Beierwaltes WH. Treatment of neuroblastoma with 131I-MIBG: Dosimetric problems and perspectives. Med Pediatr Oncol 1987;15:188-191.
28. Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50:1518-1524.
29. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: Results of a UK study. Eur J Nucl Med 1991;18:308-316.
30. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, Ackery D. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-1896.
31. Minguez P, Flux G, Genolla J, Guayambuco S, Delgado A, Fombellida JC, Sjogreen Gleisner K. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer. Med Phys 2015;42:3969-3978.
32. Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zempel SA, Normolle DP. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med 1994;21:46-52.
33. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-199.
34. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, Du Y, Lewington V, Smart J, Thom J, Zivanovic M, Johnson PW. Phase 1/2 study of fractionated (131)I-rituximab in low-grade b-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113:1412-1421.
35. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131i-anti-b1 antibody: Assessment of tumor dose-response. J Nucl Med 2003;44:260-268.
36. Yu B, Carrasquillo J, Milenic D, Chung Y, Perentesis P, Feuerestein I, Eggensperger D, Qi CF, Paik C, Reynolds J, Grem J, Curt G, Siler K, Schlom J, Allegra C. Phase I trial of iodine 131-labeled col-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996;14:1798-1809.
37. Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y. Patient-specific dosimetry using pretherapy [(1)(2)(4)I]m-iodobenzylguanidine ([(1)(2)(4)I]mIBG) dynamic PET/CT imaging before [(1)(3)(1)I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol 2015;17:284-294.
38. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Mattay KK. Impact of response to prior therapy on outcome for refractory vs. relapsed neuroblastoma patients treated with 131i-metaiodobenzylguanidine (131i-MIBG). Eur J Cancer 2015;51(16):2465-2472. doi: 10.1016/j.ejca.2015.07.023. Epub 2015 Aug 5.